Allergan CEO: Large Deal Would Be An Unlikely Outcome of Review

Allergan Chief Executive Brent Saunders said on Monday that while the company is considering large, transformational deals as part of a strategic review, they are a “very low priority and a very unlikely outcome” of the process, according to a Reuters report.

Mr. Saunders said in an interview that the five options considered in the drug company’s review are deploying capital to buy back shares, doing divestitures, splitting the company, making acquisitions, or continuing to operate Allergan as is.

He said of all the options breaking up the company would take the longest and be the most disruptive. Still, he said its something the company has to seriously consider if they determine it will create shareholder value over the long term.